Skip to main content

WASHINGTON, DC – The American Medical Informatics Association (AMIA) is pleased to announce Triomics as an AMIA Platinum Corporate Partner for the 2023 calendar year. This level of partnership means Triomics supports the association, its mission, and its members with a significant investment.

Triomics first became an AMIA corporate member in 2022 and actively participated in the Annual Symposium as a sponsor and an exhibitor. In 2023, Triomics will have a large presence at all three of AMIA’s in-person conferences, as the company plans to host engaging Corporate Roundtables and present thought-provoking Industry Partner Sessions. The Triomics team is looking forward to connecting with AMIA’s members and supporting the informatics community.

“Triomics recognizes the significance of the platform provided by AMIA for fostering fruitful exchanges of innovative ideas and promoting collaborations between industry and academia,” said Triomics Co-Founder and CEO Sarim Khan. “Our past collaborations with AMIA have been instrumental in driving our product research and development and forging successful partnerships. Moving forward, we are committed to maintaining a strong relationship with AMIA to facilitate ongoing engagement and collaboration.”

“Triomics is delivering state-of-the-art informatics solutions to automate and accelerate clinical research workflows,” said Gretchen Purcell Jackson, MD, PhD, FACS, FACMI, FAMIA, AMIA Board Chair and President, Vice President and Scientific Medical Officer, Intuitive Surgical and Associate Professor of Surgery, Pediatrics, and Biomedical Informatics, Vanderbilt University Medical Center. “Their innovations in natural-language processing and semantic standardization allow researchers to expedite the extraction of data from unstructured sources. We look forward to Triomics sharing their knowledge and experience with the AMIA community.”

AMIA’s 2023 Corporate Partnership & Membership Program recognizes industry organizations that invest in AMIA at three Corporate Partnership levels — Platinum, Gold, and Silver — and at a single Corporate Membership level. The program is designed to help these industry organization engage in AMIA, positively impacting both the association and their individual organizations. Triomics is supporting AMIA at the highest and most prestigious level.

Organizations that strategically partner with AMIA demonstrate they are industry leaders with valuable content and expertise to share. Their support enhances the association's initiatives, improves member benefits, and helps transform health and healthcare through informatics.

If corporate partnership or membership is of interest to your company, contact Vice President of Business Development Dina Santucci to start building your customized package.


About the American Medical Informatics Association

The American Medical Informatics Association, AMIA, is the leading professional association for informatics professionals and the center of action for more than 5,500 informatics professionals from 65-plus countries. As the voice of the nation’s top biomedical and health informatics professionals, AMIA and its members play a leading role in assessing the effect of health innovations on health policy and advancing the field of informatics. AMIA actively supports five domains in informatics: translational bioinformatics, clinical research informatics, clinical informatics, consumer health informatics, and public health informatics.

About Triomics

Established in 2021, Triomics is powering a host of next-generation applications of healthcare data and systems that are advancing clinical research by harnessing the growing maturity of US healthcare on FHIR and addressing its current limitations using their cutting-edge Natural Language Processing (NLP) engine. Their NLP engine automates terminology management and the extraction of useful elements from unstructured datasets, reducing the burden on clinical researchers. Triomics partners with academic medical centers and health-systems, empowering them to transcend the current performance standards in clinical research.